GlaxoSmithKline Stock News

Primary Biliary Cirrhosis Drugs Market Growth Is Driven By R&D of New Therapies Market Overview: Primary biliary cholangitis, previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in your liver are slowly destroyed. The cause of

HIV is treated with antiretroviral medicines, which work by stopping the virus replicating in the body. This allows the immune system to repair itself and prevent further damage. A combination of HIV drugs is used because HIV can quickly adapt

Cytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to treat certain skin conditions (e.g., psoriasis), rheumatoid and juvenile rheumatoid

Krabbe market research report has vital data about the market, emerging trends, product usage, motivating factors for customers and competitors. Market restraints, brand positioning, and customer behaviour is also studied in the document with which achieving a success in the

(Bloomberg) -- GlaxoSmithKline Plc told investors its aiming to develop a cure for HIV by 2030, as the company outlines its future ahead of splitting in two next year.

Complete study of the global Major Depressive Disorder (MDD) market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding

A credible Cervical Intraepithelial Neoplasia Drugs Market report involves the use of the latest tools and techniques for researching, analyzing, and gathering of data and information. This market report performs systematic gathering, recording, and analysis of data about the

A credible Hospital Infection Therapeutics Market report involves the use of the latest tools and techniques for researching, analyzing, and gathering of data and information. This market report performs systematic gathering, recording, and analysis of data about the issues related

In most cases, complicated urinary tract infection is related to a structural or neurological disease that compromises the urinary tract or host defense. Factors related to the complicated urinary tract infection comprises pregnancy, chronic renal failure, immunosuppression, catheters, urinary retention,

Epstein-Barr Virus Drug Market Research Report shows the latest market insights with upcoming trends and breakdown of the products types and application. The report provides key statistics on the market status, size, share, growth factors of the Epstein-Barr Virus Drug.

GSK, which hopes to start ground-breaking trials as soon as next summer, will provide an update to the City on its potential cure for the disease.

Mcdonald Partners LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 17.0% in the third quarter, Holdings Channel reports. The institutional investor owned 9,688 shares of the pharmaceutical companys stock after acquiring an additional 1,407 shares during the quarter. Mcdonald Partners LLCs holdings in GlaxoSmithKline were worth $370,000 as of its most recent filing with []

Berenberg Bank restated their buy rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note published on Wednesday morning, The Fly reports. GSK has been the subject of a number of other reports. JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline in a report on Monday, November 1st. UBS Group reaffirmed []

Koshinski Asset Management Inc. increased its position in GlaxoSmithKline plc (NYSE:GSK) by 49.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 8,844 shares of the pharmaceutical companys stock after acquiring an additional 2,929 shares during the period. Koshinski Asset Management Inc.s holdings in GlaxoSmithKline were worth $338,000 as of its most recent SEC []

GlaxoSmithKline plc (NYSE:GSK) Stock analysts at SVB Leerink upped their FY2021 earnings per share (EPS) estimates for GlaxoSmithKline in a report issued on Tuesday, November 23rd. SVB Leerink analyst G. Porges now expects that the pharmaceutical company will earn $3.23 per share for the year, up from their previous forecast of $3.12. SVB Leerink [] The post SVB Leerink Analysts Increase Earnings Estimates for GlaxoSmithKline plc (NYSE:GSK) appeared first on ETF Daily News .